FDAsafety guidance77% confidence
FDA AP — CYCLOBENZAPRINE HYDROCHLORIDE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Roche; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA072854. Sponsor: AIPING PHARM INC. Submission status: AP. Submission type: SUPPL. Review priority: UNKNOWN. Active ingredients: CYCLOBENZAPRINE HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Oncology · ALK Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts Supplemental Application for ALECENSA (Alectinib Hydrochloride)